Publications by authors named "B J M Van Vlijmen"

Background: Despite improvements in therapy, breast cancer still contributes to high mortality rates. Survival of these patients becomes progressively worse upon diagnosis with cancer-associated thrombosis (CAT). Unfortunately, the mechanism causing CAT has remained unclear.

View Article and Find Full Text PDF

Plasma proteins involved in coagulation and fibrinolysis are essential to hemostasis. Consequently, their circulating levels and functionality are critical in bleeding and thrombosis development. Well-established laboratory tests to assess these are available; however, said tests do not allow high multiplicity, require large volumes of plasma and are often costly.

View Article and Find Full Text PDF
Article Synopsis
  • The study looks at a protein called Von Willebrand factor (VWF) that is important for blood clotting and how it can cause problems when it's not working right.
  • Researchers used special tiny molecules called siRNAs to selectively reduce VWF levels in mice with different versions (alleles) of the VWF gene.
  • The results showed that reducing VWF helped prevent blood clots without causing bleeding issues, suggesting this method could be useful for treating certain blood disorders.
View Article and Find Full Text PDF

Background: The evaluation of a continuously evolving eHealth tool in terms of improvement and implementation in daily practice is unclear. The CMyLife digital care platform provides patient-centered care by empowering patients with chronic myeloid leukemia, with a focus on making medication compliance insightful, discussable, and optimal, and achieving optimal control of the biomarker BCR-ABL1.

Objective: The aim of this study was to investigate to what extent the participatory action research approach is suitable for the improvement and scientific evaluation of eHealth innovations in daily clinical practice (measured by user experiences) combined with the promotion of patient empowerment.

View Article and Find Full Text PDF

An imbalance in von Willebrand factor (VWF) may either lead to bleeding (von Willebrand disease, VWD) or thrombosis. Both disorders have shortcomings in the currently available treatments. VWF itself could be a potential therapeutic target because of its role in both bleeding and thrombosis.

View Article and Find Full Text PDF